Table 3.
Studies reporting proportion of patients achieving remission or LDA
| CDAI | SDAI | DAS28 | DAS28 ESR | DAS28 CRP | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| First author | Country | BARI sample size, n | Time points | LDA (n [%]) | Remission (n [%]) | LDA (n [%]) | Remission (n [%]) | LDA (n [%]) | Remission (n [%]) | LDA (n [%]) | Remission (n [%]) | LDA (n [%]) | Remission (n [%]) |
| Alten et al. [82] | France, Germany, Italy, Spain, and UK | 1073 | 12 months | BARI 2 or 4 mg cohort A: 39.4% | 24.1% (BARI 2 or 4 mg -cohort A) | NR | NR | NR | NR | NR | NR | NR | NR |
| Bayat et al. [70] | NR | 139 | 4, 12, 24, 36, 48, 60, 72, 84, and 96 weeks | NR | NR | NR | NR | NR | NR | NR |
BARI monotherapy: 96 weeks: 3.01% (remission) BARI with MTX: 96 weeks: 2.86% (remission) |
NR | NR |
| Yoshi et al. [73] | NR | 82 | 1, 2, 3, 6, 9, and 12 months | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Kemenes et al. [74] | NR | 30 | Week 24, 48 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Vassallo et al. [76] | NR | 26 | 3 months | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Barbulescu et al. [35] | Sweden | 1420 | 3 months and 1 year | NR | Differences between proportions of CDAI remissions at 1 year: 15 (11.7–18.3) | NR | NR | NR | NR | NR | NR | NR | NR |
| Fitton et al. [39] | UK | 69 | Baseline, 3 months, 6 months | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Mazarío et al. [29] | Spain | 32 | Baseline and at months 1, 3, 6, 12, 18 and 24 | NR | NR | NR | NR | NR | NR | NR | NR |
1 month: 16% After 3 months: 13% At 6 months- 64% |
1 month- 9% After 3 months- 30% At 6 months- 64% |
| Hernández-Cruz et al. [44] | Spain | 182 | 6, 12, 18 months |
6 months: 43.38 12 months: 45.69 |
6 months: 23.5 12 months: 32.45 |
6 months: 41.01 12 months: 45.34 |
6 months: 21.22 12 months: 29.66 |
NR | NR |
6 months: 16.67 12 months: 8.17 |
6 months: 56.2 12 months: 65.68 |
NR | NR |
| Edwards et al. [79] | UK | 409 | 6 months | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Alten et al. [82] | Europe | 509 | 12 months |
Total no. of patients achieving LDA: n = 382; 39.4 BARI mono: 33.8 BARI combo: 44.3 |
Total no. of patients achieving remission: n = 24.1 BARI mono: 21.8 BARI combo: 26.2 |
NR | NR | NR | NR | NR | NR | NR | NR |
| Burmester et al. [45] | EU 4 and UK | 509 | 3, 6, and 24 months | At 6 months: 36.8% | At 6 months: 25.6% | NR | NR | NR | NR | NR | NR | NR | NR |
| Yamane et al. [46]a | Japan | 7 | 2, 4, 8, and 12 weeks | Week 12; n = 5 | NR | Week 12; n = 5 | NR | NR | NR | NR | NR | Week 12; n = 2 | Week 12; n = 1 |
| Rosas et al. [47]b | Spain | 40 | Last visit | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Spinelli et al. [84] | Italy | 67 | 12 and 24 weeks | NR | NR | NR | NR | NR | NR | NR | NR |
Week 4- 51.8% Week 12- 60.7% Week 24- 70.3% |
Week 4- 27% Week 12- 32.1% Week 24- 42.2% |
| Torikai et al. [48]c | Japan | 51 | 24 weeks |
Week 24: 20.2% (Group D) Week 24: 36.6% (Group C) Week 24: 49.9% (re-initiation group) |
Week 24: 27.7% (Group D) Week 24: 56.3% (Group C) Week 24: 50.1% (re-initiation group) |
NR | NR | NR | NR | NR | NR | NR | NR |
| Gilbert et al. [49] | Switzerland | 273 | 12 months | 65.40% | 19.80% | NR | NR | NR | NR | NR | NR | NR | NR |
| Torikai et al. [50] | Japan | 32 | 3 months | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Ponce et al. [52] | Spain | JAKi: 21 (TOFA, BARI) | After treatment | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Fitton et al. [39] | UK | 39 | 3 months | NR | NR | NR | NR | NR | n = 4; 10.25% | NR | NR | NR | NR |
| Yamasaki et al. [55]d | Japan | 154 | 12 weeks |
45 (59.5%): b/tsDMARDs naïve at 12 weeks 35(46.7%): b/tsDMARDs IR group at 12 weeks |
18 (22.8%): b/tsDMARDs naïve at 12 weeks 11(14.7%): b/tsDMARDs IR group at 12 weeks |
NR | NR | NR | NR | NR | NR | NR | NR |
| Kellerhals et al. [59]e | Switzerland | 12 | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Cometi L[60]f | Italy | 100 | BL-3 M and BL-6 M | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Baldi et al. [62]g | Italy | NR | Evaluated at baseline (T0) and then after 1 month (T1), 3 months (T2), and 6 months (T3) | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Rodriguez et al. [65]h | NR | 36 (BARI and TOFA) | 6 and 12 months | NR | NR | NR | NR | NR | NR | NR |
At 6 months- 22% At 12 months- 0% |
NR | NR |
| Miyazaki et al. [17] | Japan |
Before IPTW- BARI, n = 138 After IPTW- BARI, n = 141 |
24 weeks | 115/141 = 81.6%; P = 0.02 | 57/141 = 40.4%; P = 0.04 | 115/141 = 81.5%; P = 0.02 | 64/141 = 45.4%; P = 0.04 | NR | NR | NR | NR | NR | NR |
| Kim et al. [18] | South Korea | 20 | 12 and 24 weeks | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Iwamoto et al. [19] | Japan | 81 | 24 weeks | 60.5 | 22.2 | 61.7 | 27.2 | NR | NR |
Overall, BARI: 45.7 BARI with MTX: 27.3 BARI without MTX: 26.3 |
BARI: 24.7 BARI with MTX: 26.3 BARI without MTX: 22.3 |
NR | NR |
| Asai et al. [20] | Japan | 284 and 113 patients treated with tocilizumab and BARI (before propensity score matching), BARI (n = 48) [after propensity score matching] | 24 weeks | NR | NR | NR | NR | NR | NR | NR | NR | 12.2 | 45.2 |
| Guidelli et al. [21] | Italy | 446 | 3 and 6 months |
All patients: (%) 3 months: 39.8 6 months: 44.4 12 months:42.9 bDMARD-naïve: (%) 3 months: 48.3 6 months: 45.5 12 months: 38.1 bDMARD-IR: (%) 3 months: 34.9 6 months: 43.7 12 months: 47.6 |
All patients: (%) 3 months: 12 6 months: 25 12 months: 38.9 bDMARD-naïve: (%) 3 months: 17.5 6 months: 38.2 12 months: 50.8 bDMARD-IR: (%) 3 months: 8.7 6 months: 15.8 12 months: 27 |
NR | NR | NR | NR | NR | NR |
All patients: (%) 3 months: 19.8 6 months: 15.9 12 months: 16.7 bDMARD-naïve:(%) 3 months: 21.9 6 months: 14.6 12 months: 14.3 bDMARD-IR: (%) 3 months: 18.5 6 months: 16.8 12 months: 18.7 |
All patients: (%) 3 months: 36.3 6 months: 51.6 12 months: 64.3 bDMARD-naïve: (%) 3 months: 48.3 6 months: 70 12 months: 77.8 bDMARD-IR: (%) 3 months: 29.5 6 months: 40.2 12 months: 50.8 |
| Retuerto et al. [23] | Spain | 15 | Post-treatment | NR | NR | NR | NR |
Disease activity during the first year of follow-up after start of the second JAKi: (%) 3 months: 17.3 6 months: 7.54 9 months: 18.8 12 months: 18.3 |
Disease activity during the first year of follow-up after start of the second jakinib: (%) 3 months: 29.7 6 months: 46.4 9 months: 44.1 12 months: 73.2 |
NR | NR | NR | NR |
| Spinelli et al. [84] | Italy | 59 | 4, 12, 24, and 48 weeks |
Week 4–48% Week 12–66% Week 24–66% Week 48–60% |
Week 4–12% Week 12–18% Week 24–20% Week 48–22% |
Week 4–47% Week 12–64% Week 24–63% Week 48–60% |
Week 4–12% Week 12–20% Week 24–16% Week 48–26% |
NR | NR | NR | NR |
Week 4–47% Week 12–64% Week 24–71% Week 48–56% |
Week 4–29% Week 12–40% Week 24–42% Week 48–39% |
| González-Freire et al. [25] | Spain | 20 | 6 and 12 months | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Sagdeo et al. [26] | UK | 37 | 6 months | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Tesei G[27] | Italy | 43 | 1, 3, and 6 months | NR | NR |
53.8% at 3 months 51.3% at 6 months |
5/39 (12.8%) at 3 months 8/36 (21.6%) at 6 months |
NR | NR | NR | NR | NR | NR |
| Deprez et al. [28] | France | 55 | 3, 6, and 12 months | NR | NR | NR | NR | NR | NR | NR | NR | NR | NR |
| Gonzalez et al. [29] | Spain |
All JAKi patients n = 98 (100%) BARI group n = 32 (32.65%) TOFA group n = 66 (67.35%) |
1, 3, 6, 12, 18 and 24 months | NR | NR | NR | NR |
BARI: (%) 1 month: 14% 3 months: 23% 6 months: 29% 12 months: 18% 18 months: 49% 24 months: 50% JAKi: 1 month: 16% 3 months: 13% 6 months: 28% 12 months: 23% 18 months: 50% 24 months: 33% JAKi Monotherapy: 1 month: 9% 3 months: 10% 6 months: 32% 12 months: 42% 18 months: 64% JAKi combination therapy: 1 month: 19% 3 months: 14% 6 months: 24% 12 months: 12% 18 months: 39% 24 months: 39% |
BARI: (%) 1 month: 15% 3 months: 33% 6 months: 29% 12 months: 38% 18 months: 16% 24 months: 16% JAKi: 1 month: 9% 3 months: 30% 6 months: 36% 12 months: 40% 18 months: 25% 24 months: 33% JAKi Monotherapy: 1 month: 17% 3 months: 26% 6 months: 25% 12 months: 13% 18 months: 32% JAKi combination therapy: 1 month: 10% 3 months: 35% 6 months: 45% 12 months: 52% 18 months: 19% |
NR | NR | NR | NR |
BARI baricitinib, bDMARD, biologic DMARD, CDAI Clinical Disease Activity Index, CRP C-reactive protein, csDMARD conventional synthetic DMARD, DAS28 Disease Activity Score 28-joint count, DMARD disease-modifying antirheumatic drug, ESR erythrocyte sedimentation rate, EU4 Germany, France, Spain, and Italy, IPTW inverse probability treatment weighting, IR inadequate responders, JAKi Janus kinase inhibitors, LDA low disease activity, MTX methotrexate, NR not reported, RA rheumatoid arthritis, SDAI Simple Disease Activity Index, TNF tumor necrosis factor, TOFA tofacitinib, tsMARD targeted synthetic DMARD
aPatients on TOFA-IR and TOFA were administered the drug for 3.4 months
bIn this study, 94% of patients continued concomitant treatment with some csDMARD
cPatients divided into two groups: a discontinuation group (D group; n = 23) and a continuation group (C group; n = 28)
dIn this study, 79 (51.3%) b/tsDMARDs naïve and 75 (48.7%) b/tsDMARDs-IR patients were enrolled
eIn this study, patients were treated with 4 mg BARI/day after TOFA was discontinued
fIn this study, 90 of 100 RA patients were evaluated; 49 received BARI
gAll patients had failed at least one anti-TNF
hIn this study, 4 patients received both treatments (BARI + TOFA)